ROS1 Revealed: A Cancer Conversation on the Changing Tide of NSCLC Treatment

Gain a deeper understanding of ROS1-positive NSCLC, including its biology and pathophysiology, mechanisms of resistance that limit therapy efficacy, and the newly approved or emerging ROS1-targeted treatment options available to this patient population through podcasts, downloadable slides with notes, and an expert-written ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb